Back to top
more

CRISPR Therapeutics (CRSP)

(Delayed Data from NSDQ)

$53.55 USD

53.55
1,699,042

+0.26 (0.49%)

Updated May 9, 2024 04:00 PM ET

After-Market: $53.52 -0.03 (-0.06%) 6:28 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (86 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Pfizer's Leukemia Candidate Gets Priority Review From FDA

The FDA grants a priority review to Pfizer's (PFE) NDA for leukemia candidate glasdegib for the first-line treatment of acute myeloid leukemia (AML) in combination with chemotherapy.

    Has CRISPR THERAPTC (CRSP) Outpaced Other Medical Stocks This Year?

    Is (CRSP) Outperforming Other Medical Stocks This Year?

      Kevin Cook headshot

      Dopamine and the Weather, Part 1

      How technology changes human behavior and social rules, but not human nature and genetics---yet.

        Agios Out-Licenses China Rights to Leukemia Drug Tibsovo

        Agios (AGIO) and CStone Pharmaceticals sign an exclusive collaboration and license agreement for the development and commercialization of its lead pipeline candidate Tibsovo.

          Zacks Investment Ideas feature highlights: CRISPR, Editas and Intellia

          Zacks Investment Ideas feature highlights: CRISPR, Editas and Intellia

            Kevin Cook headshot

            Knowledge, Certainty, and Destiny: How to Keep Up With Science & Technology

            Science is bringing the future to you faster every year and this requires a mind wide open.

              Paratek's Antibiotic Candidate Gets FDA Committee Date

              Paratek's (PRTK) NDA for its antibiotic candidate, omadacycline, to be reviewed by an FDA advisory committee on Aug 8.

                Kevin Cook headshot

                CRISPR Science and Stocks: Knowing Enough to Invest

                Can you learn enough about the science and the companies to invest with confidence?

                  Amgen Gets EU Nod to Add Survival Data on Blincyto's Label

                  Amgen (AMGN) gets approval from the European Commission to add overall survival (OS) data from the TOWER study on the label of its leukemia drug, Blincyto.

                    Panel Of Zacks Experts headshot

                    Top Stock Picks for the Week of June 18, 2018

                    Tracey Ryniec and Kevin Cook look at a big energy explorer and one of the hot gene editing biotechs.

                      BioMarin Begins Pediatric Study on Achondroplasia Candidate

                      BioMarin Pharmaceutical (BMRN) initiates phase II study on vosoritide for the treatment of achondroplasia in infants and children up to five years of age.

                        Idera Stock Down, Study on Dermatomyositis Candidate Fails

                        Shares of Idera (IDRA) decline following the failure of a phase II study of its pipeline candidate, IMO-8400, on adult patients with dermatomyositis.

                          Has CRISPR THERAPTC (CRSP) Outpaced Other Medical Stocks This Year?

                          Is CRISPR THERAPTC (CRSP) Outperforming Other Medical Stocks This Year?

                            Biogen Inks Deal With TMS To Acquire Phase II Stroke Asset

                            Biogen (BIIB) signs a definitive option agreement to buy TMS-007, a phase II candidate, for the treatment of acute ischemic stroke (AIS) from private biotech TMS Co., Ltd.

                              Zacks Investment Ideas feature highlights: CRISPR, Intellia Therapeutics, Editas and Vertex

                              Zacks Investment Ideas feature highlights: CRISPR, Intellia Therapeutics, Editas and Vertex

                                Vertex/CRISPR's Sickle Disease Candidate Put on Hold by FDA

                                FDA places clinical hold on a Vertex (VRTX) and CRISPR Therapeutics' IND application for CTX001 for the treatment of sickle cell disease.

                                  David Borun headshot

                                  Should You Buy the Dip in CRISPR Therapeutics?

                                  A "Clinical Hold" from the FDA has the shares falling, but is it an opportunity to get in?

                                    Is CRISPR THERAPTC (CRSP) Stock Outpacing Its Medical Peers This Year?

                                    Is CRISPR THERAPTC (CRSP) Outperforming Other Medical Stocks This Year?

                                      David Borun headshot

                                      Is Genome Editing the Next Biotech Breakthrough?

                                      CRISPR technology is promising to be the foundation the treatment of 1000s of diseases

                                        Is CRISPR THERAPTC (CRSP) Outperforming Other Medical Stocks This Year?

                                        Is CRISPR THERAPTC (CRSP) Outperforming Other Medical Stocks This Year?

                                          CRISPR Therapeutics (CRSP) Jumps: Stock Rises 12.1%

                                          CRISPR Therapeutics AG (CRSP) was a big mover last session, as the company saw its shares more than 12% on the day amid huge volumes.

                                            Brian Bolan headshot

                                            This Week In Tech Stocks

                                            A look at some tech stocks that are reporting earnings, coming out of a quiet period and one that is seeing its lockup expire today.